此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

验证血小板蛋白质组学测定方法用于诊断和监测前列腺癌

2026年11月2日 更新者:Duke University

用于诊断和监测前列腺癌的血小板蛋白质组学测定的验证:一项前瞻性研究。

This is a single center study evaluating whether a new blood test based on platelet proteins rather than plasma proteins can improve detection of prostate cancer and evaluate the degree of serious disease. Currently, doctors rely on multiple tests such as PSA, MRI scans and biopsies to do the same evaluation. Researchers are trying to see if HeLP™ can be a safe and accurate alternative.

The study is inviting men who are being seen for suspicion of prostate cancer (based on symptoms or previous lab results). If they agree to be in the study, the research team will take a sample of their blood at the time they are getting a repeat PSA test or having Imaging. The research test does not affect the care they are already receiving and takes 3 extra tubes of blood (~3 tbsp).

The research team is aiming to include 300 participants total. They believe 278 people are needed to confidently compare results between people with and without prostate cancer.

They will do an interim analysis halfway through the study, once samples from 150 subjects have been collected.

The research is considered low risk-no more uncomfortable or dangerous than a blood draw. There is a risk of loss of privacy, but researchers are taking strong steps to protect privileged information. That includes proper data handling, secure, storage, and making sure the study team is trained in research ethics.

研究概览

地位

招聘中

干预/治疗

研究类型

观察性的

注册 (估计的)

300

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • North Carolina
      • Durham、North Carolina、美国、27710
        • 招聘中
        • Duke University
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

40年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

男性

取样方法

非概率样本

研究人群

All subjects meeting eligibility criteria will be offered participation in this research study. The study is not relevant to women. The terminally ill subjects, students, children or volunteers-will not be included.

描述

Eligibility criteria

  • Patients ≥ 40 years of age
  • All patients with suspicion of PCa

Men ≥ 40 years of age attending Duke Health/Urology with suspicion of prostate cancer (Primary disease) will be approached to consent for the study. Upon consent, samples will be obtained alone, during repeat PSA/other biomarkers testing, or during imaging at Duke Lab.

Exclusion criteria

  • Men who have previously undergone treatment for prostate cancer.
  • Men with prior diagnosis of prostate cancer.
  • Men with severe, irreversible coagulopathy.
  • Men on anticoagulant therapies or those who have taken antiplatelet agents such as aspirin, NSAIDs (ibuprofen, entrophen, naproxen, diclofenac etc), clopidrogel, prasugrel, ticagrelor, or dipyridamole in the 7 days preceding blood collection.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:CASE_ONLY
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Control Group

Researchers are screening men who are suspicious of Pca, so those who will be negative for cancer will be the control group.

lab test for prostate cancer

Case Group

Researchers are screening men who are suspicious of Pca, so those who will be diagnosed will be the case group.

lab test for prostate cancer

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Levels of HeLP™ proteins in the platelets of patients suspected to have PCa
大体时间:Baseline

Researchers will define the levels of HeLP™ proteins in the platelets of patients suspected to have PCa based on assessment within Duke Health compared to standard of care like PSA, mpMRI PI-RADS and other biomarkers (if available).

Baseline
Diagnostic accuracy as reported by area under the curve (AUC)
大体时间:Baseline

Overall diagnostic accuracy of clinical variables including PSA, PI-RADS scoring, Hessian Map and other biomarkers (if available) will be determined and compared using receiving operating curve/area under curve analysis.

Baseline

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年3月11日

初级完成 (估计的)

2027年9月30日

研究完成 (估计的)

2028年9月30日

研究注册日期

首次提交

2025年8月20日

首先提交符合 QC 标准的

2025年8月20日

首次发布 (实际的)

2025年8月27日

研究记录更新

最后更新发布 (实际的)

2026年11月4日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅